Novel management strategies for idiopathic pulmonary fibrosis

References

• Raghu G, Collard HR, Egan JJ, et al. ATS/ERS/JRS/ALAT committee on idiopathic pulmonary fibrosis. an official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788–824.
   PubMed Web of Science ®Google Scholar
• Kaarteenaho R. The current position of surgical lung biopsy in the diagnosis of idiopathic pulmonary fibrosis. Respir Res. 2013;14:43.
   PubMed Web of Science ®Google Scholar
• Lynch DA, Sverzellati N, Travis WD, et al. Diagnostic criteria for idiopathic pulmonary fibrosis: a fleischner society white paper. Lancet Respir Med. 2018;6(2):138–153.
   PubMed Web of Science ®Google Scholar
• Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012;366(21):1968–1977.
   PubMed Web of Science ®Google Scholar
• Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071–2082.
   PubMed Web of Science ®Google Scholar
• Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther. 1999;291:367–373.
   PubMed Web of Science ®Google Scholar
• Nathan SD, Albera C, Bradford WZ, et al. Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis. Lancet Respir Med. 2017;5(1):33–41.
   PubMed Web of Science ®Google Scholar
• Richeldi L, Cottin V. du Bois RM, et al. Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS (®) trials. Respir Med. 2016;113:74–79.
   PubMed Web of Science ®Google Scholar
• Raghu G, Rochwerg B, Zhang Y, et al. American Thoracic Society; European Respiratory society; Japanese Respiratory Society; Latin American Thoracic Association. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: treatment of idiopathic pulmonary fibrosis. an update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med. 2015;192(2):e3–19.
   PubMed Web of Science ®Google Scholar
• Fidler L, Sitzer N, Shapera S, et al. Treatment of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis: a systematic review and meta-analysis. Chest. 2018;153(6):1405–1415.
   PubMed Web of Science ®Google Scholar
• Collum SD, Amione-Guerra J, Cruz-Solbes AS, et al. Pulmonary hypertension associated with idiopathic pulmonary fibrosis: current and future perspectives. Can Respir J. 2017;1430350:1–12.
   Google Scholar
• Mermigkis C, Bouloukaki I, Schiza SE. Sleep as a new target for improving outcomes in idiopathic pulmonary fibrosis. Chest. 2017;152(6):1327–1338.
   PubMed Web of Science ®Google Scholar
• Collard HR, Ryerson CJ, Corte TJ, et al. Acute exacerbation of idiopathic pulmonary fibrosis. an international working group report. Am J Respir Crit Care Med. 2016;194(3):265–275.
   PubMed Web of Science ®Google Scholar
• Brown AW, Kaya H, Nathan SD. Lung transplantation in IIP: a review. Respirology. 2016;21(7):1173–1184.
   PubMed Web of Science ®Google Scholar
• Romero F, Protein SR. Folding and the challenges of maintaining endoplasmic reticulum proteostasis in idiopathic pulmonary fibrosis. Ann Am Thorac Soc. 2017;Supplement5:S410–S413.
   PubMedGoogle Scholar
• Allen RJ, Porte J, Braybrooke R, et al. Genetic variants associated with susceptibility to idiopathic pulmonary fibrosis in people of European ancestry: a genome-wide association study. Lancet Respir Med. 2017;11:869–880.
   Google Scholar
• Selman M, Pardo A. Revealing the pathogenic and aging-related mechanisms of the enigmatic idiopathic pulmonary fibrosis. an integral model. Am J Respir Crit Care Med. 2014;189(10):1161–1172.
   PubMed Web of Science ®Google Scholar
• Mercer PF, Woodcock HV, Eley JD, et al. Exploration of a potent PI3 kinase/mTOR inhibitor as a novel anti-fibrotic agent in IPF. Thorax. 2016;71(8):701–711.
   PubMed Web of Science ®Google Scholar
• Ferguson KT, Torr EE, Bernau K, et al. The novel mTOR complex 1/2 inhibitor P529 inhibits human lung myofibroblast differentiation. J Cell Biochem. 2017;118(8):2241–2249.
   PubMed Web of Science ®Google Scholar
• Malouf MA, Hopkins P, Snell G. Everolimus in IPF study investigators. an investigator-driven study of everolimus in surgical lung biopsy confirmed idiopathic pulmonary fibrosis. Respirology. 2011;16(5):776–783.
   PubMed Web of Science ®Google Scholar
• Robinson CM, Neary R, Hypoxia-Induced LA. DNA hypermethylation in human pulmonary fibroblasts is associated with Thy-1 promoter methylation and the development of a pro-fibrotic phenotype. Respir Res. 2012;13(1):74.
   PubMedGoogle Scholar
• Conforti F, Davies ER, Calderwood CJ, et al. The histone deacetylase inhibitor, romidepsin, as a potential treatment for pulmonary fibrosis. Oncotarget. 2017;8(30):48737–48754.
   PubMedGoogle Scholar
• Townsley DM, Dumitriu B, Young NS. Danazol treatment for telomere diseases. N Engl J Med. 2016;375(11):1095–1096.
   PubMedGoogle Scholar
• Zank DC, Bueno M, Mora AL, et al. Idiopathic pulmonary fibrosis: aging, mitochondrial dysfunction, and cellular bioenergetics. Front Med (Lausanne). 2018;5:10.
   PubMed Web of Science ®Google Scholar
• Rehman H, Liu Q, Krishnasamy Y, et al. The mitochondria-targeted antioxidant MitoQ attenuates liver fibrosis in mice. Int Journal Phys Pathophys Pharm. 2016;8(1):14–27.
   Google Scholar
• Yu G, Tzouvelekis A, Wang R, et al. Thyroid hormone inhibits lung fibrosis in mice by improving epithelial mitochondrial function. Nat Med. 2018;24(1):39–49.
   PubMed Web of Science ®Google Scholar
• Raghu G, Martinez FJ, Brown KK, et al. CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumab. Eur Respir J. 2015;46(6):1740–1750.
   PubMed Web of Science ®Google Scholar
• Xue J, Kass DJ, Bon J, et al. Plasma B-lymphocyte stimulator (BLyS) and B-cell differentiation in idiopathic pulmonary fibrosis patients. J Immunology. 2013;191(5):2089–2095.
   PubMed Web of Science ®Google Scholar
• Parker JM, Glaspole IN, Lancaster LH, et al. A Phase 2 randomized controlled study of tralokinumab in subjects with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2018;197(1):94–103.
   PubMed Web of Science ®Google Scholar
• Hirani N, Mackinnon A, Nicol L, et al. TD139, a novel inhaled galectin-3 inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF). Results from the first in (IPF) patients study. Presented at ATS 2017, Washington (DC), 19–24 May 2017.
   Google Scholar
• Parker J, Sawtell R, Gagnon L, et al. PBI-4050 is safe and well tolerated and shows evidence of benefit in idiopathic pulmonary fibrosis. Presented at ATS 2017, Washington (DC), 19–24 May 2017.
   Google Scholar
• Raghu G, van den Blink B, Hamblin MJ, et al. Effect of recombinant human pentraxin 2 vs placebo on change in forced vital capacity in patients with idiopathic pulmonary fibrosis: a randomized clinical trial. JAMA. 2018;319(22):2299–2307.
   PubMed Web of Science ®Google Scholar
• Raghu G, Brown KK, Collard HR, et al. Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial. Lancet Respir Med. 2017;5(1):22–32.
   PubMed Web of Science ®Google Scholar
• Wilkes DS, Chew T, Flaherty KR, et al. Oral immunotherapy with type V collagen in idiopathic pulmonary fibrosis. Eur Respir J. 2015;45(5):1393–1402.
   PubMed Web of Science ®Google Scholar
• Oikonomou N, Mouratis MA, Tzouvelekis A, et al. Pulmonary autotaxin expression contributes to the pathogenesis of pulmonary fibrosis. Am J Respir Cell Mol Biol. 2012;47(5):566–574.
   PubMed Web of Science ®Google Scholar
• Maher TM, van der Aar EM, Van de Steen O, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial. Lancet Respir Med. 2018;6(8):627–635.
   PubMed Web of Science ®Google Scholar
• Zanin-Zhorov A, Weiss JM, Nyuydzefe MS, et al. Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism. Proc Natl Acad Sci U S A. 2014;111(47):16814–16819.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Huang X, Hecker L, et al. Inhibition of mechanosensitive signaling in myofibroblasts ameliorates experimental pulmonary fibrosis. J Clin Invest. 2013;123:1096–1108.
   PubMed Web of Science ®Google Scholar
• van der Velden JL, Ye Y, Nolin JD, et al. JNK inhibition reduces lung remodeling and pulmonary fibrotic systemic markers. Clin Transl Med. 2016;5(1):36.
   PubMedGoogle Scholar
• Bennett B, Blease K, Ye Y, et al. CC-90001, a second generation Jun N-Terminal Kinase (JNK) inhibitor for the treatment of idiopathic pulmonary fibrosis. Presented at ATS 2017, Washington (DC), 19–24 May 2017.
   Google Scholar
• Madala SK, Korfhagen TR, Schmidt S, et al. Inhibition of the αvβ6 integrin leads to limited alteration of TGF-α-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2014;306:L726–735.
   PubMed Web of Science ®Google Scholar
• Maden CH, Fairman D, Chalker M, et al. Safety, tolerability and pharmacokinetics of GSK3008348, a novel integrin αvβ6 inhibitor, in healthy participants. Eur J Clin Pharmacol. 2018;74(6):1–9.
   PubMed Web of Science ®Google Scholar
• Raghu G, Mouded M, Culver DA, et al. Randomized, double-blind, placebo-controlled, multiple dose, dose-escalation study of BG00011 (formerly STX-100) in patients with idiopathic pulmonary fibrosis (IPF). Presented at ATS 2018, San Diego (CA), 19–24 May 2018.
   Google Scholar
• Raghu G, Scholand MB, de Andrade J, et al. FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in IPF. Eur Respir J. 2016;47(5):1481–1491.
   PubMed Web of Science ®Google Scholar
• Tzouvelekis A, Yu G, Lino Cardenas CL, et al. SH2 domain-containing phosphatase-2 is a novel antifibrotic regulator in pulmonary fibrosis. Am J Respir Crit Care Med. 2017;195(4):500–514.
   PubMed Web of Science ®Google Scholar
• Tzouvelekis A, Paspaliaris V, Koliakos G, et al. A prospective, non-randomized, no placebo-controlled, phase Ib clinical trial to study the safety of the adipose derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosis. J Transl Med. 2013;11:171.
   PubMed Web of Science ®Google Scholar
• Chambers DC, Enever D, Ilic N, et al. A phase 1b study of placenta-derived mesenchymal stromal cells in patients with idiopathic pulmonary fibrosis. Respirology. 2014;19(7):1013–1018.
   PubMed Web of Science ®Google Scholar
• Glassberg MK, Minkiewicz J, Toonkel RL, et al. Allogeneic human mesenchymal stem cells in patients with idiopathic pulmonary fibrosis via intravenous delivery (AETHER): a phase i safety clinical trial. Chest. 2017;151(5):971–981.
   PubMed Web of Science ®Google Scholar
• Serrano-Mollar A, Gay-Jordi G, Guillamat-Prats R, et al. Pneumocyte study group. safety and tolerability of alveolar type II cell transplantation in idiopathic pulmonary fibrosis. Chest. 2016;150(3):533–543.
   PubMed Web of Science ®Google Scholar
• Vancheri C, Kreuter M, Richeldi L, et al. INJOURNEY trial investigators. nintedanib with add-on pirfenidone in idiopathic pulmonary fibrosis. results of the INJOURNEY trial. Am J Respir Crit Care Med. 2018;197(3):356–363.
   PubMed Web of Science ®Google Scholar
• Idiopathic Pulmonary Fibrosis Clinical Research Network, Da Z, Schwarz M, Kj A, et al. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med. 2010;363(7):620–628.
   PubMed Web of Science ®Google Scholar
• Behr J, Nathan SD, Harari S, et al. Sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: A Phase IIb, randomised, double-blind, placebo-controlled study - rationale and study design. Respir Med. 2018;138:13–20.
   PubMed Web of Science ®Google Scholar
• Sun T, Liu J, Zhao DW. Efficacy of N-acetylcysteine in idiopathic pulmonary fibrosis: a systematic review and meta-analysis. Azim A Ed Medicine. 2016;95(19):e3629.
   Google Scholar
• Behr J, Bendstrup E, Crestani B, et al. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir Med. 2016;4(6):445–453.
   PubMed Web of Science ®Google Scholar
• Shea BS, Probst CK, Brazee PL, et al. Uncoupling of the profibrotic and hemostatic effects of thrombin in lung fibrosis. JCI Insight. 2017;2(9):e86608.
   PubMed Web of Science ®Google Scholar
• Kubo H, Nakayama K, Yanai M, et al. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest. 2005 Sep;128(3):1475–1482.
   PubMed Web of Science ®Google Scholar
• Noth I, Anstrom KJ, Calvert SB, et al. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2012;186(1):88–95.
   PubMed Web of Science ®Google Scholar
• Sd N, Cs K. Treatment of pulmonary hypertension in idiopathic pulmonary fibrosis: shortfall in efficacy or trial design? Drug Des Devel Ther. 2014;8:875–885.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Hino M, Gemma A. Potential benefit of bosentan therapy in borderline or less severe pulmonary hypertension secondary to idiopathic pulmonary fibrosis-an interim analysis of results from a prospective, single-center, randomized, parallel-group study. BMC Pulm Med. 2017;17(1):200.
   PubMedGoogle Scholar
• Corte TJ, Keir GJ, Dimopoulos K, et al. Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia. Am J Respir Crit Care Med. 2014;190(2):208–217.
   PubMed Web of Science ®Google Scholar
• Couluris M, Kinder BW, Xu P, et al. Treatment of idiopathic pulmonary fibrosis with losartan: a pilot project. Lung. 2012;190(5):523–527.
   PubMed Web of Science ®Google Scholar
• Fastrès A, Felice F, Roels E, et al. The lung microbiome in idiopathic pulmonary fibrosis: a promising approach for targeted therapies. Int Mol Sci. 2017;18(12):2735.
   Web of Science ®Google Scholar
• Shulgina L, Cahn AP, Chilvers ER, et al. Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: a randomised controlled trial. Thorax. 2013;68(2):155–162.
   PubMed Web of Science ®Google Scholar
• Egan JJ, Adamali HI, Lok SS. Ganciclovir antiviral therapy in advanced idiopathic pulmonary fibrosis: an open pilot study. Pulm Med. 2011;240805:2011.
   Google Scholar
• Arai T, Tachibana K, Sugimoto C, et al. High-dose prednisolone after intravenous methylprednisolone improves prognosis of acute exacerbation in idiopathic interstitial pneumonias. Respirology. 2017;22(7):1363–1370.
   PubMed Web of Science ®Google Scholar
• Kondoh Y, Cottin V, Brown KK. Recent lessons learned in the management of acute exacerbation of idiopathic pulmonary fibrosis. Eur Respir Rev. 2017;26:145.
   Web of Science ®Google Scholar
• Donahoe M, Valentine VG, Chien N, et al. Autoantibody-targeted treatments for acute exacerbations of idiopathic pulmonary fibrosis. PLoS One. 2015;10(6):e0127771.
   PubMed Web of Science ®Google Scholar
• Kreuter M, Spagnolo P, Wuyts W, et al. Antacid therapy and disease progression in patients with idiopathic pulmonary fibrosis who received pirfenidone. Respiration. 2017;93(6):415–423.
   PubMed Web of Science ®Google Scholar
• Raghu G, Morrow E, Collins BF, et al. Laparoscopic anti-reflux surgery for idiopathic pulmonary fibrosis at a single centre. Eur Respir J. 2016;48(3):826–832.
   PubMed Web of Science ®Google Scholar
• Leslie KO. Idiopathic pulmonary fibrosis may be a disease of recurrent, tractional injury to the periphery of the aging lung: a unifying hypothesis regarding etiology and pathogenesis. Arch Pathol Lab Med. 2012;136(6):591–600.
   PubMed Web of Science ®Google Scholar
• Dowman LM, McDonald CF, Hill CJ, et al. The evidence of benefits of exercise training in interstitial lung disease: a randomized controlled trial. Thorax. 2017;72(7):610–619.
   PubMed Web of Science ®Google Scholar
• Vainshelboim B, Kramer MR, Izhakian S. Physical activity and exertional desaturation are associated with mortality in idiopathic pulmonary fibrosis. J Clin Med. 2016;5(8):pii–E73.
   Web of Science ®Google Scholar
• Ryerson CJ, Camp PG, Eves ND, et al. High oxygen delivery to preserve exercise capacity in patients with idiopathic pulmonary fibrosis treated with nintedanib. methodology of the HOPE-IPF study. Ann Am Thorac Soc. 2016;13(9):1640–1647.
   PubMed Web of Science ®Google Scholar
• Bell EC, Cox NS, Goh N, et al. Oxygen therapy for interstitial lung disease: a systematic review. Eur Respir Rev. 2017;26:143.
   Web of Science ®Google Scholar
• Kolilekas L, Manali E, Vlami KA, et al. Sleep oxygen desaturation predicts survival in idiopathic pulmonary fibrosis. J Clin Sleep Med. 2013;9(6):593–601.
   PubMed Web of Science ®Google Scholar
• Lindell KO, Liang Z, Hoffman LA, et al. Palliative care and location of death in decedents with idiopathic pulmonary fibrosis. Chest. 2015;147(2):423–429.
   PubMed Web of Science ®Google Scholar
• Horton MR, Santopietro V, Mathew L, et al. Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis: a randomized trial. Ann Intern Med. 2012;157(6):398–406.
   PubMed Web of Science ®Google Scholar
• Mj VM, Ss B, Vancheri C, et al. Cough in idiopathic pulmonary fibrosis. Eur Respir Rev. 2016;25(141):278–286.
   PubMed Web of Science ®Google Scholar
• Abdulqawi R, Dockry R, Holt K, et al. P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study. Lancet. 2015;385(9974):1198–1205.
   PubMed Web of Science ®Google Scholar